Partial
Partially Aligned
Patient Risk:
Low
Summary
Some general product/class/administration claims are supported by the provided label excerpts (e.g., mechanism/class and oral dosing/indication), but multiple safety-relevant and formulation/administration claims cannot be verified from the excerpts and several mechanistic/role claims are not supported as written.
Category Scores
Accurate Statements
Qulipta is a medication for chronic migraine.
Section 1 INDICATIONS AND USAGE (preventive treatment of migraine in adults; includes chronic migraine in provided context via Section 14.2 Chronic Migraine).
Qulipta is designed for migraine prevention.
Section 1 INDICATIONS AND USAGE (preventive treatment of migraine in adults); Sections 14.1/14.2 (preventive treatment studies).
Qulipta belongs to the class of calcitonin gene-related peptide (CGRP) receptor antagonists.
Section 12.1 Mechanism of Action (Atogepant is a CGRP receptor antagonist).
Qulipta blocks the action of CGRP at its receptor.
Section 12.1 Mechanism of Action (CGRP receptor antagonist).
Qulipta is taken orally.
Section 2 DOSAGE AND ADMINISTRATION (QULIPTA is taken orally with or without food).
Unsupported Statements
Qulipta is believed to prevent vasodilation and inflammation associated with migraine attacks.
Not supported by the provided label excerpts.
Common side effects of Qulipta include constipation, nausea, and fatigue.
Partially aligned: label excerpt lists nausea, constipation, and fatigue/somnolence as most common adverse reactions; however the statement does not reflect the label’s wording exactly (fatigue/somnolence) and provides no incidence context. Treated as partially unsupported detail.
Qulipta is a prescription medication that requires a doctor's order to obtain.
Not stated in the provided label excerpts.
Qulipta is not available over-the-counter.
Not stated in the provided label excerpts.
Qulipta was originally developed by Allergan.
Not stated in the provided label excerpts.
AbbVie acquired Allergan in May 2020 and integrated its products, including Qulipta, into AbbVie's offerings.
Not stated in the provided label excerpts.
Qulipta is manufactured by AbbVie.
Not stated in the provided label excerpts.
AbbVie's manufacturing facilities are involved in the production of Qulipta.
Not stated in the provided label excerpts.
AbbVie operates a global network of manufacturing facilities.
Not stated in the provided label excerpts.
AbbVie's manufacturing sites are situated in the United States, Ireland, Switzerland, and Singapore.
Not stated in the provided label excerpts.
AbbVie acquired Allergan, the original developer of Qulipta, in 2020.
Not stated in the provided label excerpts.
Contradictions
Important Omissions
Specific dosing details (strengths and dosing frequency) for episodic vs chronic migraine were not provided in the AI statements (e.g., 10 mg/30 mg/60 mg once daily for episodic migraine; 60 mg once daily for chronic migraine).
Importance:
Moderate
Key warnings relevant to safe use (hypersensitivity; hypertension; Raynaud’s phenomenon) were not mentioned in the AI statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements that are label-supported are largely descriptive (indication mechanism, oral administration). However, several safety-relevant elements from the label are omitted, and some statements are unsupported by the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts (notably manufacturing/developer/history, prescription/OTC status, and mechanistic speculation), and label-required safety/dosing details are omitted.
Suggested Improvement
Limit claims to what is supported by the provided label excerpts: preventive treatment in adults; atogepant is a CGRP receptor antagonist; oral administration; and, for safety accuracy, align adverse reaction and warning statements with the label’s terminology (e.g., fatigue/somnolence; hypersensitivity/HTN/Raynaud’s) and include key dosing specifics when discussing regimen.